Loader

Pathways

PathWhiz ID Pathway Meta Data

PW000561

Pw000561 View Pathway
disease

Lysinuric Protein Intolerance (LPI)

Homo sapiens
Lysinuric protein intolerance (LPI), also called hyperdibasic aminoaciduria, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of the kidney function pathway. It is caused by a mutation in the SLC7A7 gene which encodes the Y+L amino acid transporter 1 protein, which is involved in the uptake of amino acids, both with sodium for neutral amino acids, and without for dibasic amino acids. In this disorder, the amino acids lysin, arginine and ornithine, found in protein, cannot be broken down, which can cause problems in the systems that use these amino acids, such as the urea cycle. LPI is characterized by a shortage of lysine, arginine and ornithine within the body, causing elevated ammonia levels in the blood. Symptoms of the disorder include failure to thrive after weaning, nausea and vomiting following a meal containing large amounts of protein, as well as osteoporosis, and lung and kidney problems. Treatment with a protein restricted diet is effective, as well as prescription of medication to lower the levels of ammonia in the blood. It is estimated that the LPI affects 1 in 60,000 individuals in certain populations such as in Finland and Japan, and less frequently outside these populations.

PW121904

Pw121904 View Pathway
disease

Lysinuric Protein Intolerance (LPI)

Mus musculus
Lysinuric protein intolerance (LPI), also called hyperdibasic aminoaciduria, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of the kidney function pathway. It is caused by a mutation in the SLC7A7 gene which encodes the Y+L amino acid transporter 1 protein, which is involved in the uptake of amino acids, both with sodium for neutral amino acids, and without for dibasic amino acids. In this disorder, the amino acids lysin, arginine and ornithine, found in protein, cannot be broken down, which can cause problems in the systems that use these amino acids, such as the urea cycle. LPI is characterized by a shortage of lysine, arginine and ornithine within the body, causing elevated ammonia levels in the blood. Symptoms of the disorder include failure to thrive after weaning, nausea and vomiting following a meal containing large amounts of protein, as well as osteoporosis, and lung and kidney problems. Treatment with a protein restricted diet is effective, as well as prescription of medication to lower the levels of ammonia in the blood. It is estimated that the LPI affects 1 in 60,000 individuals in certain populations such as in Finland and Japan, and less frequently outside these populations.

PW122128

Pw122128 View Pathway
disease

Lysinuric Protein Intolerance (LPI)

Rattus norvegicus
Lysinuric protein intolerance (LPI), also called hyperdibasic aminoaciduria, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of the kidney function pathway. It is caused by a mutation in the SLC7A7 gene which encodes the Y+L amino acid transporter 1 protein, which is involved in the uptake of amino acids, both with sodium for neutral amino acids, and without for dibasic amino acids. In this disorder, the amino acids lysin, arginine and ornithine, found in protein, cannot be broken down, which can cause problems in the systems that use these amino acids, such as the urea cycle. LPI is characterized by a shortage of lysine, arginine and ornithine within the body, causing elevated ammonia levels in the blood. Symptoms of the disorder include failure to thrive after weaning, nausea and vomiting following a meal containing large amounts of protein, as well as osteoporosis, and lung and kidney problems. Treatment with a protein restricted diet is effective, as well as prescription of medication to lower the levels of ammonia in the blood. It is estimated that the LPI affects 1 in 60,000 individuals in certain populations such as in Finland and Japan, and less frequently outside these populations.

PW002532

Pw002532 View Pathway
metabolic

Lysolipid Incorporation into ER

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.

PW002780

Pw002780 View Pathway
metabolic

Lysolipid Incorporation into ER PC(10:0/10:0)

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.

PW002783

Pw002783 View Pathway
metabolic

Lysolipid Incorporation into ER PC(14:0/14:0)

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.

PW002784

Pw002784 View Pathway
metabolic

Lysolipid Incorporation into ER PC(16:0/16:0)

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.

PW002786

Pw002786 View Pathway
metabolic

Lysolipid Incorporation into ER PC(16:1(11Z)/16:1(11Z))

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.

PW002785

Pw002785 View Pathway
metabolic

Lysolipid Incorporation into ER PC(16:1(9Z)/16:1(9Z))

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.

PW002787

Pw002787 View Pathway
metabolic

Lysolipid Incorporation into ER PC(18:0/18:0)

Saccharomyces cerevisiae
Lysolipids such as lysophosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylserine and lysophosphatidylinositol get transported into the cell through a phospholipid ATPase. Once in the cytosol they are incorporated into the ER membrane through a Ale1p transport membrane where phosphatidylcholine is generated.